Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world data on palbociclib combo for breast cancer in japan

NCT ID NCT05399329

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked back at medical records of 693 Japanese patients with a certain type of advanced breast cancer (HR+/HER2-) who received palbociclib plus endocrine therapy as their first or second treatment. Researchers measured how long patients lived without the cancer getting worse and overall survival. The goal is to see how well this treatment works in everyday practice, not just in clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
palbociclib plus endocrine therapy
What this could lead to
If successful, this study could confirm that palbociclib plus endocrine therapy works well in real-world Japanese patients, supporting its continued use.
What could go wrong
This is a retrospective observational study, not a controlled trial, so results may be influenced by patient selection or missing data. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

693 people

The number who actually took part.

Started

Apr 2022

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study uses secondary data of multiple sites by utilizing medical record review approach for those who have been diagnosed with ABC in Japan.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of HR+/HER2- ABC * Age of 20 years or older at diagnosis of ABC * Patients that received palbociclib plus ET in the first line or second line * Patients who meet the criteria regarding the medical record below: * Patients with any medical records (regardless of palbociclib use) for more than 6 months from palbociclib initiation OR * Patients with any medical records for less than 6 months from palbociclib initiation AND who had specific events (death, disease progression, or treatment discontinuation of palbociclib due to adverse events) in the available records Exclusion Criteria: * Patients who received chemotherapy as first line treatment. * Patients who have previously participated or are participating in any interventional clinical trials that include investigational or marketed products. (Interventional clinical trials for early breast cancer and later line after palbociclib will be acceptable, Besides, patients participating in other investigator-initiated research or noninterventional studies can be included as long as their standard of care is not altered by the study.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Aichi Cancer Center

    Nagoya, 464-8681, Japan

  • Gifu University Hospital

    Gifu, 501-1194, Japan

  • Hiroshima University Hospital

    Hiroshima, 734-8551, Japan

  • Hokkaido Cancer Center

    Sapporo, Hokkaido, 003-0804, Japan

  • Ishikawa Prefectural Central Hospital

    Kanazawa, Ishikawa-ken, 920-8530, Japan

  • Japan Community Health care Organization Kurume General Hospital

    Kurume, Fukuoka, 830-0013, Japan

  • Jichi Medical University Hospital

    Shimotsuke, Tochigi, 329 0498, Japan

  • Kaizuka City Hospital

    Kaizuka, Osaka, 597-0015, Japan

  • Kitasato University Hospital

    Sagamihara, Kanagawa, 252-0329, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Hospital Organization Osaka National Hospital

    Osaka, 540-0006, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, 791-0280, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, 541-8567, Japan

  • Osaka University Hospital

    Suita, Osaka, 565-0871, Japan

  • Saitama Prefectural Cancer Center

    Kita-adachi-gun, Saitama, 362-0806, Japan

  • Seirei Hamamatsu General Hospital

    Hamamatsu, Shizuoka, 430-8558, Japan

  • Shizuoka Prefectural Hospital Organization

    Shizuoka, 420-8527, Japan

  • Showa University Hospital

    Tokyo, 142-8666, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, 980-8574, Japan

  • Tokai University Hospital

    Kanagawa, 259-1193, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.